Lukas Leu
CanadaPortfolio ManagerMale4.2Global Dominance: 0.00%Lukas Leu is a portfolio manager at Bellevue, a healthcare investment specialist, known for his insights into the pharmaceutical industry. In a recent context, he criticized Novo Nordisk's communication regarding their clinical study results for the obesity medication CagriSema, highlighting the company's failure to meet expectations and provide transparent information.
Country presence
Recent news mentions
Lukas Leu from ATG Healthcare Investments sees competitors like Roche and Novartis benefiting from a potential merger.
Gerüchte um Megafusion zwischen AstraZeneca und BMS irritieren den Markt
Switzerland· 2026-08-03
Lukas Leu raised concerns about the impact of a merger on innovation and growth for AstraZeneca.
AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma dealCanada· 2026-08-03
Novo shareholder Lukas Leu, a portfolio manager at ATG Healthcare, said Novo’s cost-cutting measures fell short of reassuring investors.
Novo Nordisk cuts 9,000 jobs as it fends off competition in weight-loss drugsCanada· 2025-09-10
Lukas Leu criticized Novo Nordisk's communication regarding the study results.
Vom Börsenstar zum Sorgenkind – findet Novo Nordisk zurück in die Spur?Switzerland· 2025-08-07
